Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 14/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 14/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 13/20 | 0.48 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.47 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.43 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.43 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.43 |
| ▸ | PI4KA | P42356 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL942547 | 0.88 | PIK3CA (0.61) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL11938407 | 0.86 | PIK3CA (0.43) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL11938406 | 0.85 | PIK3CA (0.42) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL13806078 | 0.82 | PIK3CA (0.76) | PIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL11938399 | 0.81 | PIK3CA (0.75) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL13781900 | 0.76 | PIK3CA (0.80) | PIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL924512 | 0.76 | PIK3CG (0.61) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL11938367 | 0.74 | PIK3CA (0.78) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL571448 | 0.74 | PIK3CG (0.71) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3C3 | |
| SCHEMBL1939184 | 0.73 | PIK3CA (0.69) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227462-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2012-07-24 | — | — | US | disclosed |
| US-20100105711-A1 | Organic Compounds | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105711-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | PIK3CA 2/4885PIK3CD 3/4885PIK3CG 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.